CytoSorbents Launches Program to Reduce Workforce and Costs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Should l Buy CTSO?
Workforce Reduction: CytoSorbents has implemented a strategic plan that includes a 10% reduction in workforce to optimize operations and reduce costs.
Financial Outlook: The company aims to achieve operating cash flow break-even by Q1 2026 and anticipates a restructuring charge of up to $900K.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CTSO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CTSO
Wall Street analysts forecast CTSO stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 0.696
Low
0.75
Averages
0.75
High
0.75
Current: 0.696
Low
0.75
Averages
0.75
High
0.75
About CTSO
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cytosorbents to Announce Q4 Earnings on March 25
- Earnings Announcement Schedule: Cytosorbents is set to release its Q4 2023 earnings report on March 25 after market close, with stakeholders keenly awaiting performance insights to gauge future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.05, reflecting a significant 66.7% year-over-year decline, indicating challenges in profitability that may affect investor confidence.
- Revenue Forecast: Revenue is projected at $9.21 million, representing a modest 0.7% year-over-year increase, suggesting some market demand despite sluggish growth, which could inform future strategic adjustments.
- Historical Performance Review: Over the past two years, Cytosorbents has only beaten EPS estimates 13% of the time and revenue estimates 38% of the time, highlighting volatility in achieving financial targets, necessitating cautious evaluation of its financial stability.
See More
CytoSorbents Launches HotSwap™ to Optimize Critical Care Treatment
- Launch of HotSwap™: CytoSorbents introduces HotSwap™, designed to expedite the exchange of CytoSorb adsorbers for critically ill patients, enhancing treatment efficiency and reducing nursing workload, thereby improving patient outcomes and survival rates.
- Renewal of Strategic Partnership: The renewal of the exclusive distribution agreement with Aferetica Srl strengthens market position in Italy, with over a decade of collaboration facilitating the widespread adoption of CytoSorb in critical care and cardiac surgery.
- Supportive Clinical Data: At ISICEM 2026, CytoSorbents presented new clinical data showing significant improvements in vasopressor requirements, oxygenation, and fluid balance for ICU patients treated with CytoSorb, with an ICU mortality rate of 32.7%, lower than predicted.
- Enhanced Scientific Leadership: The symposium hosted by CytoSorbents at ISICEM emphasized the importance of personalized treatment, showcasing its leadership in blood purification and further solidifying CytoSorb's role as a frontline therapy across critical illnesses.
See More
CytoSorbents Launches HotSwap™ to Optimize Critical Care Therapy
- Launch of HotSwap™: CytoSorbents introduced HotSwap™ at the ISICEM in Brussels, designed for rapid, seamless exchange of CytoSorb adsorbers during critical patient treatment, significantly enhancing treatment efficiency and helping clinicians better manage conditions to reduce organ failure risks.
- Renewal of Strategic Partnership: The company renewed its exclusive distribution agreement with Aferetica Srl, a collaboration exceeding a decade that has successfully promoted CytoSorb's clinical adoption in Italy, with plans to continue innovating in blood purification and organ transplantation to improve patient care.
- Clinical Data Presentation: At ISICEM 2026, CytoSorbents showcased multiple clinical data sets, including the COSMOS registry with 306 patients, reinforcing the application value of CytoSorb across various critical illnesses and boosting clinician confidence in the therapy.
- Optimistic Market Outlook: With the launch of HotSwap™ and the deepening of strategic partnerships, CytoSorbents is poised to strengthen its market position in critical care treatment, which is expected to drive future revenue growth and increase market share.
See More
CytoSorbents Announces Q4 and Full Year 2025 Earnings Release Date
- Earnings Release Schedule: CytoSorbents Corporation will report its fourth quarter and full year 2025 earnings on March 25, 2026, with management hosting a live webcast at 4:30 PM ET to discuss financial performance and future outlook.
- Wide Technology Application: CytoSorbents' blood purification technology is utilized in over 70 countries, with more than 300,000 devices used cumulatively, primarily aimed at removing toxic substances during cardiac surgeries and in intensive care, significantly reducing patient mortality risk.
- FDA Breakthrough Device Designation: The company is developing the DrugSorb®-ATR system to mitigate perioperative bleeding in high-risk surgeries, having received two FDA Breakthrough Device Designations, indicating strong potential in anticoagulant removal.
- Optimistic Market Outlook: With its technology applicable to various critical illnesses, CytoSorbents is poised for growth through ongoing innovation and market expansion, enhancing its competitive position in the global healthcare market.
See More
CytoSorbents (CTSO) Projects $37M Revenue for 2025, FDA Meeting Scheduled
- Financial Outlook: CytoSorbents anticipates fourth quarter and full-year 2025 revenues of approximately $9.2 million and $37 million, respectively, with expected gross margins between 73% and 75%, indicating stable growth potential in the market.
- FDA Meeting Scheduled: The company plans to hold a Pre-Submission Meeting with the FDA this month regarding DrugSorb®-ATR, with a De Novo application expected to be filed this quarter and a regulatory decision anticipated in mid-2026, paving the way for market entry.
- Research Publication: Results from the pivotal STAR-T study for DrugSorb®-ATR have been accepted for publication in a top cardiac surgery journal, reflecting the clinical relevance of the technology and potentially enhancing the company's reputation and market recognition in the medical community.
- Operational Improvements: The company is implementing various process improvements and a global strategic workforce and cost reduction program, expecting to accelerate its path to profitability and achieve approximately operating cash flow break-even in Q1 2026, thereby strengthening its financial health.
See More
CytoSorbents Reports $37M in Q3 Sales; CEO to Join Virtual Discussion
- Strong Sales Performance: CytoSorbents achieved $37 million in high-margin sales over the trailing 12 months, reflecting robust market demand in critical care and cardiac surgery, thereby establishing a solid foundation for future growth.
- Accelerated Regulatory Progress: The company is actively pursuing FDA approval for DrugSorb™-ATR, with a key regulatory decision expected in mid-2026, which will provide crucial support for expanding its product line and market penetration.
- Executive Participation in Discussion: CEO Phillip Chan and CFO Peter J. Mariani will join a virtual discussion hosted by D. Boral Capital on December 15, offering insights into the company's recent financial performance and future strategies, aimed at bolstering investor confidence.
- Innovative Technology Outlook: CytoSorbents' blood purification technology is utilized in over 70 countries with nearly 300,000 devices used cumulatively, showcasing its broad application potential in treating life-threatening conditions and further solidifying the company's leadership in the medical technology sector.
See More
Cytosorbents to Announce Q4 Earnings on March 25
- Earnings Announcement Schedule: Cytosorbents is set to release its Q4 2023 earnings report on March 25 after market close, with stakeholders keenly awaiting performance insights to gauge future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.05, reflecting a significant 66.7% year-over-year decline, indicating challenges in profitability that may affect investor confidence.
- Revenue Forecast: Revenue is projected at $9.21 million, representing a modest 0.7% year-over-year increase, suggesting some market demand despite sluggish growth, which could inform future strategic adjustments.
- Historical Performance Review: Over the past two years, Cytosorbents has only beaten EPS estimates 13% of the time and revenue estimates 38% of the time, highlighting volatility in achieving financial targets, necessitating cautious evaluation of its financial stability.
See More
CytoSorbents Launches HotSwap™ to Optimize Critical Care Treatment
- Launch of HotSwap™: CytoSorbents introduces HotSwap™, designed to expedite the exchange of CytoSorb adsorbers for critically ill patients, enhancing treatment efficiency and reducing nursing workload, thereby improving patient outcomes and survival rates.
- Renewal of Strategic Partnership: The renewal of the exclusive distribution agreement with Aferetica Srl strengthens market position in Italy, with over a decade of collaboration facilitating the widespread adoption of CytoSorb in critical care and cardiac surgery.
- Supportive Clinical Data: At ISICEM 2026, CytoSorbents presented new clinical data showing significant improvements in vasopressor requirements, oxygenation, and fluid balance for ICU patients treated with CytoSorb, with an ICU mortality rate of 32.7%, lower than predicted.
- Enhanced Scientific Leadership: The symposium hosted by CytoSorbents at ISICEM emphasized the importance of personalized treatment, showcasing its leadership in blood purification and further solidifying CytoSorb's role as a frontline therapy across critical illnesses.
See More
CytoSorbents Launches HotSwap™ to Optimize Critical Care Therapy
- Launch of HotSwap™: CytoSorbents introduced HotSwap™ at the ISICEM in Brussels, designed for rapid, seamless exchange of CytoSorb adsorbers during critical patient treatment, significantly enhancing treatment efficiency and helping clinicians better manage conditions to reduce organ failure risks.
- Renewal of Strategic Partnership: The company renewed its exclusive distribution agreement with Aferetica Srl, a collaboration exceeding a decade that has successfully promoted CytoSorb's clinical adoption in Italy, with plans to continue innovating in blood purification and organ transplantation to improve patient care.
- Clinical Data Presentation: At ISICEM 2026, CytoSorbents showcased multiple clinical data sets, including the COSMOS registry with 306 patients, reinforcing the application value of CytoSorb across various critical illnesses and boosting clinician confidence in the therapy.
- Optimistic Market Outlook: With the launch of HotSwap™ and the deepening of strategic partnerships, CytoSorbents is poised to strengthen its market position in critical care treatment, which is expected to drive future revenue growth and increase market share.
See More
CytoSorbents Announces Q4 and Full Year 2025 Earnings Release Date
- Earnings Release Schedule: CytoSorbents Corporation will report its fourth quarter and full year 2025 earnings on March 25, 2026, with management hosting a live webcast at 4:30 PM ET to discuss financial performance and future outlook.
- Wide Technology Application: CytoSorbents' blood purification technology is utilized in over 70 countries, with more than 300,000 devices used cumulatively, primarily aimed at removing toxic substances during cardiac surgeries and in intensive care, significantly reducing patient mortality risk.
- FDA Breakthrough Device Designation: The company is developing the DrugSorb®-ATR system to mitigate perioperative bleeding in high-risk surgeries, having received two FDA Breakthrough Device Designations, indicating strong potential in anticoagulant removal.
- Optimistic Market Outlook: With its technology applicable to various critical illnesses, CytoSorbents is poised for growth through ongoing innovation and market expansion, enhancing its competitive position in the global healthcare market.
See More
CytoSorbents (CTSO) Projects $37M Revenue for 2025, FDA Meeting Scheduled
- Financial Outlook: CytoSorbents anticipates fourth quarter and full-year 2025 revenues of approximately $9.2 million and $37 million, respectively, with expected gross margins between 73% and 75%, indicating stable growth potential in the market.
- FDA Meeting Scheduled: The company plans to hold a Pre-Submission Meeting with the FDA this month regarding DrugSorb®-ATR, with a De Novo application expected to be filed this quarter and a regulatory decision anticipated in mid-2026, paving the way for market entry.
- Research Publication: Results from the pivotal STAR-T study for DrugSorb®-ATR have been accepted for publication in a top cardiac surgery journal, reflecting the clinical relevance of the technology and potentially enhancing the company's reputation and market recognition in the medical community.
- Operational Improvements: The company is implementing various process improvements and a global strategic workforce and cost reduction program, expecting to accelerate its path to profitability and achieve approximately operating cash flow break-even in Q1 2026, thereby strengthening its financial health.
See More
CytoSorbents Reports $37M in Q3 Sales; CEO to Join Virtual Discussion
- Strong Sales Performance: CytoSorbents achieved $37 million in high-margin sales over the trailing 12 months, reflecting robust market demand in critical care and cardiac surgery, thereby establishing a solid foundation for future growth.
- Accelerated Regulatory Progress: The company is actively pursuing FDA approval for DrugSorb™-ATR, with a key regulatory decision expected in mid-2026, which will provide crucial support for expanding its product line and market penetration.
- Executive Participation in Discussion: CEO Phillip Chan and CFO Peter J. Mariani will join a virtual discussion hosted by D. Boral Capital on December 15, offering insights into the company's recent financial performance and future strategies, aimed at bolstering investor confidence.
- Innovative Technology Outlook: CytoSorbents' blood purification technology is utilized in over 70 countries with nearly 300,000 devices used cumulatively, showcasing its broad application potential in treating life-threatening conditions and further solidifying the company's leadership in the medical technology sector.
See More
